HER2-positive Early Breast Cancer
8 clinical trials · Condition
◉ Watch HER2-positive Early Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (NCT05113251) | AstraZeneca | 2021-10-25 |
| Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients (NCT04750122) | Peking University People's Hospital | 2021-03-28 |
| A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer (NCT03989037) | Shanghai Institute Of Biological Products | 2019-06-27 |
| A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (NCT03674112) | Hoffmann-La Roche | 2018-12-19 |
Track HER2-positive Early Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.